The pre-requisite of a second-generation glioma PET biomarker.
Since the introduction of FDG into the field of molecular imaging with positron emission tomography (PET) more than three decades ago, FDG has been the tracer of choice for oncology PET imaging. Despite the relative disadvantages of FDG and the relative benefits of its challengers, FDG remains the most commonly used glioma tracer nowadays. The present article surveys the expectations of the field and gives a concise summary of recent developments; including the issues pertaining to the continued search for an optimal second-generation PET biomarker for glioma.


CONCLUSIONS
The present article gives a concise summary of recent developments; including the issues pertaining to the continued search for an optimal PET biomarker for glioma.
Borbely
Katalin
K
PET/CT Amb, National Institute of Oncology, 1122 Budapest, Rath Gyorgy 7-9, Hungary. katalin.borbely@oncol.hu
Wintermark
Max
M
Martos
Janos
J
Fedorcsak
Imre
I
Bognar
Laszlo
L
Kasler
Miklos
M
D015415:Biomarkers; D001932:Brain Neoplasms / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D005910:Glioma / Q000000981:diagnostic imaging*; D006801:Humans; D049268:Positron-Emission Tomography / Q000379:methods* / Q000639:trends; D019275:Radiopharmaceuticals
D015415:Biomarkers; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18